Securisyn Medical

Executive Summary

Securisyn Medical is a Denver-based private medical device company focused on improving patient safety during mechanical ventilation through its SolidAIRity® Airway Stabilization System. The system is a novel endotracheal tube securement device designed to prevent unplanned extubations (UEs), a critical adverse event in intensive care units that can lead to severe complications, prolonged hospital stays, and increased costs. With FDA approval already secured, Securisyn is now transitioning from a development-stage company to a commercial entity, targeting the significant unmet need in airway management. The global market for endotracheal tube securement devices is estimated to exceed $500 million annually, driven by rising awareness of UE risks and value-based care initiatives. Securisyn’s solution offers a differentiated approach by combining secure fixation with ease of use and reduced skin breakdown, addressing limitations of current taping and commercial holder methods. The company’s mission to establish a new standard of care positions it well for adoption in leading hospital systems, especially as clinicians seek to reduce preventable adverse events. While still early in commercialization, Securisyn’s validated technology and clear clinical rationale support a favorable risk-reward profile for investors seeking exposure to innovative medical devices with strong safety and cost-saving narratives.

Upcoming Catalysts (preview)

• Q2 2026First major hospital system contract for SolidAIRity system60% success
• Q3 2026Publication of peer-reviewed clinical outcomes data demonstrating reduction in unplanned extubations70% success
• Q4 2026Reimbursement code assignment or favorable coverage decision from Medicare55% success